2g9x: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:2g9x.png|left|200px]] | [[Image:2g9x.png|left|200px]] | ||
{{STRUCTURE_2g9x| PDB=2g9x | SCENE= }} | {{STRUCTURE_2g9x| PDB=2g9x | SCENE= }} | ||
===Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor NU6271=== | ===Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor NU6271=== | ||
{{ABSTRACT_PUBMED_16669651}} | {{ABSTRACT_PUBMED_16669651}} | ||
==About this Structure== | ==About this Structure== | ||
[[2g9x]] is a 4 chain structure of [[Cell Division Protein Kinase 2]] and [[Cyclin]] with sequence from [http://en.wikipedia.org/wiki/Bos_taurus Bos taurus] and [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2G9X OCA]. | |||
==See Also== | |||
*[[Cell Division Protein Kinase 2|Cell Division Protein Kinase 2]] | |||
*[[Cyclin|Cyclin]] | |||
==Reference== | ==Reference== | ||
<ref group="xtra">PMID: | <ref group="xtra">PMID:016669651</ref><references group="xtra"/> | ||
[[Category: Bos taurus]] | [[Category: Bos taurus]] | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
| Line 35: | Line 27: | ||
[[Category: Serine/threonine protein kinase]] | [[Category: Serine/threonine protein kinase]] | ||
[[Category: Transferase]] | [[Category: Transferase]] | ||
[[Category: Transferase-cell cycle complex]] | |||
Revision as of 12:23, 25 July 2012
Structure of Thr 160 phosphorylated CDK2/cyclin A in complex with the inhibitor NU6271
Template:ABSTRACT PUBMED 16669651
About this Structure
2g9x is a 4 chain structure of Cell Division Protein Kinase 2 and Cyclin with sequence from Bos taurus and Homo sapiens. Full crystallographic information is available from OCA.
See Also
Reference
- Griffin RJ, Henderson A, Curtin NJ, Echalier A, Endicott JA, Hardcastle IR, Newell DR, Noble ME, Wang LZ, Golding BT. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination. J Am Chem Soc. 2006 May 10;128(18):6012-3. PMID:16669651 doi:10.1021/ja060595j